Pfizer, Inc. (NYSE:PFE) has been given a $39.00 price objective by equities research analysts at J P Morgan Chase & Co in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target would indicate a potential upside of 9.98% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday. Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday. UBS AG set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Finally, BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $38.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 earnings per share.

WARNING: “Pfizer, Inc. (PFE) PT Set at $39.00 by J P Morgan Chase & Co” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-pt-set-at-39-00-by-j-p-morgan-chase-co/1674583.html.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders have sold 389,621 shares of company stock valued at $13,298,598 over the last three months. Insiders own 0.06% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its stake in Pfizer by 1.3% in the third quarter. Principal Financial Group Inc. now owns 14,802,058 shares of the biopharmaceutical company’s stock worth $528,433,000 after acquiring an additional 186,790 shares during the period. Access Financial Services Inc. lifted its stake in Pfizer by 14.7% in the third quarter. Access Financial Services Inc. now owns 44,259 shares of the biopharmaceutical company’s stock worth $1,580,000 after acquiring an additional 5,672 shares during the period. Oregon Public Employees Retirement Fund lifted its stake in Pfizer by 1.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 1,652,936 shares of the biopharmaceutical company’s stock worth $59,010,000 after acquiring an additional 19,989 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI lifted its stake in Pfizer by 2.8% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 224,950 shares of the biopharmaceutical company’s stock worth $8,031,000 after acquiring an additional 6,088 shares during the period. Finally, Blackhill Capital Inc. lifted its stake in Pfizer by 9.8% in the third quarter. Blackhill Capital Inc. now owns 511,201 shares of the biopharmaceutical company’s stock worth $18,250,000 after acquiring an additional 45,773 shares during the period. 69.01% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.